Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × INDUSTRY × mCRPC × Clear all

Phase

Status

Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 268 Neoplasms 161 Breast Neoplasms 157 Colorectal Neoplasms 96 Melanoma 94 Multiple Myeloma 91 Neoplasm Metastasis 87 Ovarian Neoplasms 77 Prostatic Neoplasms 76 Carcinoma, Renal Cell 72 Recurrence 71 Lung Neoplasms 63 Stomach Neoplasms 62 Squamous Cell Carcinoma of Head and Neck 61 Lymphoma, Non-Hodgkin 56 Pancreatic Neoplasms 53 Leukemia, Myeloid, Acute 52 Leukemia, Lymphocytic, Chronic, B-Cell 50 Carcinoma, Hepatocellular 45 Triple Negative Breast Neoplasms 44 Lymphoma, Large B-Cell, Diffuse 44 Small Cell Lung Carcinoma 39 Head and Neck Neoplasms 37 Urinary Bladder Neoplasms 36 Glioblastoma 36 Lymphoma 35 Endometrial Neoplasms 34 Parkinson Disease 4, Autosomal Dominant Lewy Body 33 Lymphoma, Follicular 32 Uterine Cervical Neoplasms 29

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡